OTTAWA, Feb. 1, 2012 /CNW/ - The following is a statement by Russell Williams, President of Canada's
Research-Based Pharmaceutical Companies (Rx&D) on the announcement by
the Government of Canada today to ensure that personalized medicine
will allow for more effective treatments, thus supporting our Canadian
health care system in a more sustainable way.
"Canada's Research-Based Pharmaceutical Companies welcome this
commitment by the Government of Canada to establish personalized
medicine as the way to transform the delivery of health care to
"At Rx&D, we believe that providing the right medicine with the right
dose to the right patient at the right time is crucial to improving
health outcomes for Canadians. With the rise of chronic disease and an
aging population, all governments are grappling with unprecedented
demand for health care services. It is clear that we face a collective
challenge to sustain and improve our health care system where
traditional approaches are no longer efficient.
"We commend the Government of Canada's commitment to engage in this
work. Pharmaceutical innovation is a proven tool to help Canadians live
longer, healthier, more productive lives. It is critical to the future
productivity of our country, our workplaces, our communities and our
citizens. Innovation is essential for "patient-centered" care.
"The development of new and more effective medicines and vaccines
continues to change the face of health care in Canada. Canadians now
survive life threatening illnesses and live with chronic conditions in
ways not possible for previous generations.
"We applaud the Canadian Institutes of Health Research, Genome Canada
and the Cancer Stem Cell Consortium for their vision and leadership to
develop and implement a scientific innovation that will result in
better health for Canadians."
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information: